Novo Nordisk’s Bear Case Is Priced In — But the Pipeline Tells a Different Story
20.06.2026 - 21:24:46 | boerse-global.de
The market has spent the past year punishing Novo Nordisk shares, slicing nearly 40% off the stock in 12 months. That brutal reassessment reflects genuine headwinds: price cuts on GLP-1 drugs for US government-insured patients, Eli Lilly’s stranglehold on more than 60% of the domestic market, and a data disappointment from CagriSema that saw 23% weight loss at 84 weeks versus 25.5% for Lilly’s Zepbound. At Friday’s close of €38.90, the stock still trades about 5.5% below its 200-day moving average of €41.16.
Yet a single headline is beginning to carve a new narrative: three million oral Wegovy prescriptions in just 22 weeks. That blistering launch pace — one of the strongest US pharmaceutical debuts by volume — lifted Novo Nordisk shares 3.21% on Friday, the biggest single-day gain in weeks. The oral formulation, long considered a tougher sell than injections, is proving its doubters wrong. The UK has already granted approval, and the United Arab Emirates market is live. International launches beyond the US are slated for the second half of 2026.
A Foundation Bet on the Metabolic Frontier
The same week, the Novo Nordisk Foundation — the controlling shareholder — injected new capital into the ecosystem. Its “CardioMetabolic Bridge” program, worth around $69 million, will fund research into obesity, type 2 diabetes, and related conditions over six years. Coordinated by the BioInnovation Institute in Copenhagen, the project opens its first lab in London this month, with additional sites planned in Germany and Italy. The foundation signaled that promising drug candidates could feed back into Novo Nordisk’s internal pipeline.
That long-term thinking dovetails with a broader pipeline that extends well beyond the GLP-1 class. At the ADA Congress in New Orleans, Novo Nordisk unveiled Phase 2 data for Zenagamtide: the highest 40 mg dose cut HbA1c by an average 1.71 percentage points over 36 weeks, with nearly 89% of participants reaching the clinically relevant threshold below 7%. Body weight dropped 14.6%. Phase 3 begins later this year. Separately, the REIMAGINE-1-to-3 Phase 3 trials all met their primary and key secondary endpoints, with results published simultaneously in The Lancet and The Lancet Diabetes & Endocrinology.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Sickle Cell Sleeper
Perhaps the most underappreciated development sits outside metabolic disease altogether. Etavopivat, a potential first-in-class therapy for sickle cell disease, delivered pivotal Phase 3 data in April. The HIBISCUS study hit both co-primary endpoints: a 27% reduction in vaso-occlusive crises versus placebo, and a median time to first crisis of 38.4 weeks versus 20.9 weeks. Novo Nordisk will file for approval in the second half of 2026. The asset came via the $1.1 billion acquisition of Forma Therapeutics in 2022, and a Phase 2 trial in beta-thalassemia is also underway. For a drug targeting roughly eight million patients worldwide, the analyst chatter has been conspicuously quiet.
Price Cuts as a Volume Wager
The bear case is not baseless. Novo Nordisk expects a slight revenue decline in 2026 after slashing prices on GLP-1 medicines for both government-funded plans and cash-paying patients. The strategy, however, is a calculated volume bet: lower out-of-pocket costs should drive a disproportionate increase in filled prescriptions. And from mid-2026, Medicare will cover obesity drugs for certain beneficiaries for the first time, a structural expansion that could pressure private insurers to follow suit.
On the capital front, Novo Nordisk has been aggressively buying back shares. Since February, it has acquired roughly 19.9 million B-shares for 5.27 billion Danish kroner as part of a 15 billion kroner annual program. That buying, combined with the recent price action, has stabilised the technical picture. The stock now trades above both its 50-day (€36.99) and 100-day moving averages, with a relative strength index of 58.2 — momentum without overheating. The real test remains the 200-day line at €41.16; a sustainable close above that level would signal a genuine trend shift.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Deutsche Bank, for its part, keeps a “Hold” rating with a DKK 290 target, citing the 2031 patent cliff and low expectations for the upcoming “Zeus” clinical readout. That caution is understandable, but the asymmetry is shifting. The 52-week low of €30.25 from March now stands nearly 29% in the rear-view mirror. The path back to the old highs is long and execution-dependent, but a company launching a record-setting oral pill, advancing a Phase 3-ready amylin candidate, publishing strong diabetes data in top-tier journals, and preparing a first-in-class sickle cell filing is not a one-trick pony running out of tricks. The market’s story is incomplete — and the next chapters are already being written.
Ad
Novo Nordisk Stock: New Analysis - 20 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
